Do You Really Need a ₹1 Lakh Clinical Test? When a Consumer DNA Kit Is Enough

The genetic testing aisle has split in two directions in India. At one end: consumer kits from ₹6,999 to ₹17,999, marketed as insights for the curious. At the other: hospital-based clinical genetic tests ranging from ₹15,000 for a targeted gene panel to ₹1,50,000 and above for clinical whole exome sequencing. If you are trying to decide which you need - or whether the consumer kit is just a cheaper substitute for the clinical test - this guide explains the actual difference, and when each is the right tool.

The honest answer is that these two categories of test are not competitors. They are different tools designed for different questions. Knowing which question you are asking is the entire decision.

What Clinical Genetic Tests Actually Test

The term "clinical genetic test" covers several distinct technologies, each suited to different diagnostic questions.

Targeted Gene Panels

A targeted panel sequences specific genes known to be associated with a condition. For example, a BRCA1/2 panel sequences the entire coding regions of both genes to identify all variants - common and rare - that might cause hereditary breast and ovarian cancer. An LDLR/APOB/PCSK9 panel covers the main familial hypercholesterolemia genes. A targeted Lynch syndrome panel covers MLH1, MSH2, MSH6, PMS2, and EPCAM.

Cost in Indian hospitals: typically ₹15,000 - ₹40,000 depending on the number of genes and the laboratory. Results are interpreted by a certified genetic pathologist and carry diagnostic weight - they can be used to make clinical decisions.

Whole Exome Sequencing (WES)

WES sequences all protein-coding regions of the genome - approximately 2% of the total, but the portion that contains most known disease-causing variants. It is used when a targeted panel has not yielded a diagnosis, or when the clinical picture is complex and the causative gene is not obvious. Typical cost in Indian hospitals: ₹40,000 - ₹80,000, with a clinical report signed by a certified genetic pathologist and usually accompanied by genetic counseling sessions.

Clinical Whole Genome Sequencing (WGS)

Clinical WGS sequences the entire genome at high coverage (typically 30x or more), capturing not just coding variants but also intronic, regulatory, and structural variants. It is the most comprehensive but also the most expensive test: ₹80,000 - ₹2,00,000 or more in Indian hospitals. Clinical WGS is usually ordered only when other approaches have not yielded a diagnosis, or for specific indications such as rare pediatric disorders or complex oncology cases.

Other Clinical Approaches

Chromosomal microarray detects chromosomal duplications and deletions too small to be seen under a microscope but too large to be captured by sequence-based tests - commonly used in pediatric developmental delay and congenital anomaly workups. FISH (fluorescence in situ hybridisation) detects specific chromosomal rearrangements and is widely used in hematological malignancy and cytogenetics. These are specific tools for specific questions; they are not alternatives to consumer DNA tests in any meaningful sense.

What Consumer DNA Tests Actually Test

Consumer DNA tests - including Helixline's Origins and Decode - use a technology called SNP genotyping (or DNA microarray). Rather than sequencing your entire genome, the chip reads approximately 700,000 pre-selected positions in your DNA - positions where common genetic variants (single nucleotide polymorphisms, or SNPs) are known to exist. This is not sequencing. It is reading known variant positions, not discovering new ones.

What this means in practice:

• Coverage: The test reads ~700,000 out of ~3,200,000,000 positions in your genome. It covers only positions that appear on the chip design - it misses structural variants, large insertions and deletions, and rare novel variants not included in the chip's design.
• Clinical validation: Consumer test results are not clinically validated for diagnostic use. They cannot be submitted as diagnostic evidence or used to make clinical decisions without confirmatory clinical testing.
• What they do well: Consumer kits are precisely designed for the questions they answer - ancestry, common variant associations, polygenic risk scores, pharmacogenomics for well-characterised SNPs, and carrier screening for common recessive variants. For these applications, they are genuinely good tools.

What consumer tests do well, specifically:

• BRCA1/2 common founder variants: Consumer tests cover the common pathogenic variants responsible for the majority of hereditary breast cancer in identifiable founder populations. They do not cover the full spectrum of rare novel BRCA variants - for that, full gene sequencing is necessary.
• Pharmacogenomics for characterised SNPs: CYP2C19, CYP2D6, SLCO1B1, TPMT, VKORC1, CYP2C9 - these are well-characterised, actionable pharmacogenomic markers that consumer tests cover reliably.
• Carrier screening for common recessive conditions: Cystic fibrosis, spinal muscular atrophy - common variants are covered. Rare novel variants are not.
• Ancestry and population genomics: Consumer tests are purpose-built for this. Clinical tests are not designed for it at all.

When You Need a Clinical Test - Not Negotiable

There are situations where a consumer DNA test is not the appropriate tool, and where using one instead of a clinical test would be genuinely harmful - not just suboptimal. These include:

• A clinician has referred you for genetic testing based on symptoms, family history, or an established clinical indication. If a physician has recommended genetic testing, that recommendation reflects a clinical judgment about what question needs to be answered. A consumer kit will not answer it.
• Personal or family history of hereditary cancer - breast cancer before age 45, bilateral breast cancer, ovarian cancer at any age, multiple first-degree relatives with cancer, male breast cancer. These clinical features warrant clinical-grade full gene sequencing, not a consumer chip.
• A child has a developmental disorder or multiple congenital anomalies requiring a diagnostic workup. Clinical chromosomal microarray or whole exome sequencing are the appropriate tools; consumer tests are not designed for pediatric diagnostics.
• IVF and preimplantation genetic testing (PGT) - requires clinically validated results from accredited laboratories. Consumer tests cannot be used for this purpose.
• Prenatal genetic testing - NIPT, amniocentesis, CVS - these are clinical procedures ordered by obstetricians and gynecologists. Consumer tests are entirely separate from prenatal diagnostics.
• A physician needs the genetic result to make a treatment decision - if a prescribing physician needs pharmacogenomic data to justify a dosing decision and document it in a medical record, a clinical pharmacogenomic test from an accredited lab is the appropriate tool.
• Any situation where the genetic result will directly inform a clinical decision - surgery, chemoprevention, medication choice, clinical trial eligibility. Consumer test results should not be the basis for clinical decisions without confirmatory clinical testing.

When a Consumer Kit Is Sufficient - and Genuinely Useful

For a large category of questions, a consumer kit is not merely an acceptable substitute for a clinical test - it is the right tool, and a clinical test would be overkill, expensive, and potentially confusing rather than helpful.

Ancestry and Heritage Research

Consumer kits are purpose-built for ancestry. Helixline's Origins analyses your DNA against 200+ South Asian reference populations, providing community-level ancestry estimates, ANI/ASI proportions, and haplogroup assignments for both paternal and maternal lineages. Clinical tests are not designed for ancestry analysis and would not produce this information.

Pharmacogenomics Awareness

Knowing that you are a slow metaboliser of CYP2C19 substrates - which include clopidogrel (a blood thinner), many PPIs, and several antidepressants - is actionable information even without clinical-grade documentation. You raise it with your prescribing physician. They can factor it in to medication choices or order a clinical pharmacogenomic test if formal documentation is needed. The consumer result opens a conversation that would not otherwise happen.

Carrier Screening for Family Planning

Decode covers common variants for cystic fibrosis, spinal muscular atrophy, sickle cell trait, thalassemia-associated variants, and Fragile X premutation - conditions with significant prevalence in specific Indian communities. If you and your partner are both carriers for the same condition, that is a meaningful signal that warrants a conversation with a genetic counselor and potentially a more comprehensive clinical carrier panel. The consumer test is the appropriate starting point; the clinical test follows where indicated.

Health Predisposition as a Preventive Conversation Starter

A consumer health genetics report can identify genetic signals for elevated cardiovascular risk, Type 2 diabetes predisposition, or Alzheimer's risk - not as clinical diagnoses, but as flags that motivate earlier preventive screening and more proactive lifestyle management. "I have a genetic signal for elevated cardiovascular risk - should we start lipid screening earlier?" is a legitimate, actionable question to bring to your physician, based on a consumer test result.

Population and Community Ancestry Research

Consumer DNA tests are specifically designed for population genomics and community ancestry analysis. Clinical tests have no role here at all. For anyone interested in understanding their community's genetic heritage, how their family fits within the larger South Asian genetic landscape, or what their haplogroups reveal about deep ancestral migrations - a consumer kit is the only appropriate tool.

The Smart Two-Step Approach

For most people who are not presenting with a specific clinical indication, the most efficient strategy is a two-step approach that uses each type of test for what it does best.

Step 1: Consumer kit for broad exploration. Helixline's Decode at ₹12,999 covers ancestry (200+ South Asian reference populations, haplogroups), pharmacogenomics (CYP2C19, CYP2D6, SLCO1B1, TPMT, VKORC1, CYP2C9, and others), carrier screening (common variants for conditions common in Indian communities), health predisposition signals across dozens of conditions, and wellness traits. This is a comprehensive sweep of your genetic landscape using the tool that is designed for it.

Step 2: Clinical testing for anything that warrants follow-up. If Decode flags a BRCA carrier status signal, the next step is clinical-grade full BRCA1/2 sequencing at an accredited lab, interpreted by a certified genetic counselor and oncologist. The consumer result motivates and prioritises; the clinical test confirms and validates. If Decode suggests a high pharmacogenomic risk for statin-induced muscle damage, you discuss it with your physician. If they want formal documentation in your medical record, a clinical pharmacogenomic test follows.

This two-step approach is significantly more efficient than jumping directly to ₹60,000 - ₹80,000 clinical WES for non-specific health curiosity. Clinical WES without a clear indication frequently returns variants of uncertain significance (VUS) - variants that cannot currently be classified as either harmful or harmless, causing anxiety without actionable conclusions. A targeted consumer sweep first identifies which areas of your genome are worth clinical-grade investigation.

The Cost Comparison: What You Actually Get at Each Price Point

Test	Price (approx.)	Technology	Clinical validity	Best for
Helixline Origins	₹6,999	SNP genotyping (~700k positions)	Not clinical diagnostic	Ancestry, haplogroups, wellness traits
Helixline Decode	₹12,999	SNP genotyping (~700k positions)	Not clinical diagnostic	Ancestry + pharmacogenomics + carrier screening + health predisposition
Helixline Infinite	₹17,999	Whole genome sequencing (raw data)	Not clinical diagnostic report	Most complete personal genomic data; advanced ancestry; shareable with clinical geneticist
Clinical targeted panel	₹15,000 - ₹40,000	Full sequencing of specific genes	Clinically validated, NABL/CAP lab	Specific hereditary disease diagnosis; carrier confirmation; clinical documentation
Clinical WES	₹40,000 - ₹80,000	All protein-coding regions sequenced	Clinically validated, certified genetic pathologist report	Undiagnosed rare diseases; complex clinical presentations; when targeted panels are unrevealing
Clinical WGS	₹80,000 - ₹2,00,000+	Entire genome sequenced at high coverage	Clinically validated; highest sensitivity for rare variants	Rare pediatric disorders; complex oncology; when WES is unrevealing; requires clinical indication

A Note on Infinite

Helixline's Infinite (₹17,999) sits in an interesting position in this landscape. It provides whole genome sequencing - the same underlying technology as clinical WGS - but it is not a clinical diagnostic product. The results are raw genomic data and a personal genomics report, not a signed clinical report from a certified genetic pathologist in an NABL-accredited diagnostic lab.

Infinite is appropriate for users who want the most complete genetic dataset possible for personal research, detailed ancestry analysis, and broad exploration of their own genome. It is not a substitute for clinical WGS where a clinical indication exists.

However, Infinite data offers a meaningful pathway: the raw data can be taken to a clinical geneticist or a bioinformatics service for interpretation. A clinical geneticist who reviews high-quality WGS data - even from a personal genomics product - can often provide insights that approximate what a clinical WGS report would contain, at a substantially lower total cost than hospital WGS alone. This makes Infinite a reasonable option for well-informed users who want comprehensive data and plan to work with a clinician to interpret it, but it remains outside the formal clinical testing framework.

Understanding What Consumer Tests Cannot Catch

The most important limitation of consumer SNP-based tests is that they are designed to read known variant positions. They cannot detect:

• Rare novel variants - a new or rare pathogenic variant in BRCA1 that does not appear on the chip design will not be detected. Full gene sequencing by a clinical laboratory is necessary to catch the full spectrum of rare variants.
• Structural variants - large chromosomal duplications, deletions, inversions, and translocations are invisible to SNP arrays. Clinical chromosomal microarray or WGS is needed.
• Mosaic variants - mutations present in only a fraction of cells (often arising post-fertilisation) may be missed or underestimated by SNP arrays. Clinical testing with appropriate mosaic detection thresholds is required.
• Trinucleotide repeat expansions - conditions like Huntington's disease, myotonic dystrophy, and Fragile X syndrome are caused by repeat expansions that are not reliably captured by standard SNP arrays. Specific PCR-based clinical tests are required.

This is not a criticism of consumer tests - it is a description of the technology. SNP arrays are not designed to detect these categories of variant. Knowing what a test cannot detect is as important as knowing what it can.

Frequently Asked Questions

If I find a BRCA variant in my Decode results, do I need a clinical BRCA test?

Yes - and this is the intended use of consumer carrier screening. Decode tests for common BRCA1/2 founder variants responsible for the majority of hereditary breast cancer in certain populations. If a variant is flagged, the next step is a clinical-grade full BRCA1/2 sequencing panel at an accredited lab, interpreted by a certified genetic counselor and oncologist. The consumer result identifies who should prioritise clinical follow-up; it does not replace the clinical test. Think of it as a triage tool: the consumer test tells you where to look; the clinical test tells you what is there.

My doctor suggested a ₹60,000 whole exome sequencing test. Should I do Decode first?

Only if your doctor has not established a clear clinical indication. If your physician has recommended WES based on symptoms, family history, or an established clinical question - do the WES. Consumer kits test a fundamentally different set of variants and will not answer the clinical question that prompted the WES recommendation. If, however, you are considering WES out of general curiosity or preventive interest without a specific clinical indication, discussing this with a genetic counselor first is worthwhile. VUS (variants of uncertain significance) are common in WES without a specific indication and frequently cause more anxiety than clarity. A genetic counselor can help determine whether WES is the right tool for your question or whether a targeted panel or consumer test would serve you better.

Can I use Helixline's Infinite as a clinical test?

Infinite provides whole genome sequencing data, but it is not a clinical diagnostic product - it does not come with a signed clinical report from a certified genetic pathologist and is not conducted in a NABL/CAP-accredited diagnostic lab with the validation standards those designations require. The raw data can be shared with a clinical geneticist or bioinformatics service for further interpretation, and a clinician reviewing good-quality WGS data may be able to provide meaningful insights. But for formal clinical decision-making - where a documented clinical result is required - a properly validated clinical WGS or WES from an accredited diagnostic lab is the appropriate tool.

Does Decode cover pharmacogenomics at a clinically useful level?

The pharmacogenomics section in Decode covers the most clinically relevant and well-characterised SNPs in this space: CYP2C19 (clopidogrel, PPIs, several antidepressants), CYP2D6 (codeine, tamoxifen, many antidepressants and antipsychotics), SLCO1B1 (statin-induced myopathy risk), TPMT (thiopurine drugs used in autoimmune disease and some cancers), VKORC1 and CYP2C9 (warfarin dosing), and several others. These are validated pharmacogenomic markers with strong clinical evidence and published guidelines from CPIC (Clinical Pharmacogenomics Implementation Consortium). While not a replacement for a formal clinical pharmacogenomic test where medical documentation is needed, the Decode pharmacogenomics section provides genuinely actionable conversation points with prescribing physicians - particularly for anyone starting statin therapy, antidepressants, or anticoagulants.

I am healthy and just want to know if I am a carrier for anything serious before planning a family. Is Decode enough?

Decode is a reasonable and appropriate starting point for pre-conception carrier screening. It covers common variants for conditions with meaningful prevalence in Indian communities: cystic fibrosis, spinal muscular atrophy, sickle cell trait, thalassemia-associated variants, and Fragile X premutation, among others. The important caveat: Decode tests the common variants on its SNP array, not every possible disease-causing variant in each gene. A comprehensive clinical carrier panel - which sequences the full gene rather than reading selected positions - has higher sensitivity and will capture rare variants that the consumer test may miss. For family planning, the recommended approach is to use Decode as a starting point, then discuss your results with a genetic counselor who can advise whether expanded clinical carrier screening is warranted based on your specific community background, family history, and partner's results.